BRAF and neoplasm: The HDAC6 inhibitors nexturastat A and tubastatin A inhibited the proliferation of various BRAF-mutant and - wildtype melanoma cell lines (including the BRAF-mutant WM983A and WM793 cells) and augmented the antitumor immunity of treated tumor cells by upregulated expression of MHCI and melanoma antigens (gp100, MART1, TYRP1, and TYRP2)[119].